This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 3, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax
® personalized immune therapies for solid tumor cancers, announced today the availability on the web of several interviews of their CEO
Linda Powers on the floor of the New York Stock Exchange on
May 1, 2013 by FOX Business News (FOX), the Huffington Post, and the International Business Times, amongst others.
In the FOX interview, Ms. Powers described the importance of NW Bio's DCVax technology in mobilizing a patient's whole immune system, and in targeting the full set of biomarkers on the cancer. This way, the DCVax treatment involves many active agents hitting many targets on the cancer, rather than just a single active agent hitting a single target, as is typical with cancer drugs and some other types of immune therapies. Ms. Powers explained that NW Bio's approach makes it harder for the tumor to "escape," which the Company believes is responsible for the striking results in clinical trials so far, adding years of survival in patients (rather than weeks or months) and doing so without toxicity. These results are clearly differentiating NW Bio from other players in this burgeoning field.
You can see the FOX interview at
In the Huffington Post and New York Financial Press interview, Ms. Powers outlined in more detail the process for combining the tumor tissue biomarkers with the dendritic cells (master immune cells), obtained through a blood draw from the patient, to create the vaccine. Additionally, she stressed the significance of key regulatory approvals obtained in the US and
Europe, relating to Phase III clinical trials and Phase I/II trials for both operable and inoperable tumors that provide NW Bio with multiple opportunities for success.
You can view the Huffington Post interview at
In the International Business Times interview, Ms. Powers recounted the cost saving potential of the DCVax platform, which positions NW Bio well in the face of the rapidly rising costs of less effective conventional cancer treatments. Ms. Powers explained the two main versions of the NW Bio vaccines, for operable and inoperable tumors, in all solid tumor cancers (cancers in any tissues of the body), as well as the ultimate power of the immune system and the consistent, positive results obtained in clinical trials to date with DCVax treatments for several diverse types of cancers.